Photo of Eric K. Singhi from mdanderson.org
Oct 5, 2024, 02:12
Eric K. Singhi: FDA Oncology approves amivantamab and chemo for EGFR and NSCLC
Eric K. Singhi shared a post on X:
“FDA Oncology approves amivantamab and chemo for EGFR+ mNSCLC after TKI progression per phase 3 MARIPOSA-2 study:
-
- PFS: 6.3 v 4.2 mos (HR 0.48)
- ORR: 53% v 29%
- No OS difference at interim (HR 0.73)
- AEs: rash, IRR, nail toxicity, stomatitis.”
Source: Eric K. Singhi/X
Dr. Eric K. Singhi is a thoracic and head and neck medical oncologist, currently serving as an Assistant Professor in the Department of General Oncology within the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center in Houston, TX.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 11, 2025, 18:14
May 11, 2025, 18:05
May 11, 2025, 17:07
May 11, 2025, 16:57
May 11, 2025, 16:49